**Author Relationships With Industry and Other Entities (Comprehensive)—2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter**

| **Committee Member** | **Employment** | **Consultant** | **Speaker** | **Ownership/ Partnership/ Principal** | **Research** | **Institutional, Organizational, or Other Financial Benefit** | **Expert Witness** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Paul Heidenreich, *Chair* | Stanford VA Palo Alto  Health Care System —  Professor of Medicine | None | None | None | None | None | None |
| N. A. Mark III Estes | Tufts Medical Center — Professor of Medicine | * Boston Scientific† * Medtronic† * St. Jude Medical† | None | None | * Boston Scientific | * IBHRE \* * Medtronic† * St. Jude Medical† * Boston Scientific† | None |
| Gregg C.  Fonarow | Ahmanson-UCLA  Cardiomyopathy  Center Division of  Cardiology — Director | * Amgen * Janssen * Bayer * Boston Scientific * Johnson & Johnson * Medicines Company * Medtronic * Novartis† * Takeda | None | None | * Gambro * Medtronic * NHLBI† * NIH/NIAID† * Novartis† | * ACCF/AHA Task Force on Data Standards\* * ACCF/AHA Task Force on Performance Measures\* * ACTION Registry GWTG Steering Committee Chair\* * AHA Consumer Health Quality Coordinating Committee\* * AHA Manuscript Oversight Committee\* * GWTG Steering Committee (PRT)\* * JAMA Cardiology * Medtronic- IMPROVE HF Steering Committee\* | None |
| Corrine Y. Jurgens | Stony Brook University School of Nursing —Associate Professor | None | None | None | None | None | None |
| David D. McManus | University of  Massachusetts Memorial  Medical Center — Assistant Professor of Medicine | None | None | * ATRIA\* | * Biotronik - IMPACT study * Philip healthcare – SENTINEL-HF study | None | 2011 Defendant, lead malpositioned |
| Robert L. McNamara | Yale University School of  Medicine Section of  Cardiology — Associate  Professor of Medicine | None | None | None | None | * American Heart Association† * Pfizer, Inc. | * 2013-Defendant, Perioperative echocardiography |
| Joseph E. Marine | Johns Hopkins School of Medicine — Associate  Professor of Medicine | None | None | None | None | None | None |
| Penelope Solis | American College of Cardiology | None | None | None | None | None | None |

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a *relevant* relationship IF: a) the *relationship or interest* relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the *document*; or b) the *company/entity* (with whom the relationship exists) makes a drug, drug class, or device addressed in the *document*, or makes a competing drug or device addressed in the *document*; or c) the *person or a member of the person’s household* has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the *document*.

\*No financial relationship.

†Significant (greater than $5,000) relationship.

ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; GWTG, Get With The Guidelines; IBHRE, International Board of Heart Rhythm Examiners; IMPACT; IMPROVE HF, Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; PRT, Pharmacy Round Table; UCLA, University of California, Los Angeles; NIH/NIAID, National Institute Health/ The National Institute of Allergy and Infectious Diseases; NHBLI, National Heart, Lung, and Blood Institute; SENTINEL-HF study and VA, Veterans Affairs.